CLINICAL CHARACTERISTICS, TREATMENT PATTERNS AND HEALTH CARE UTILIZATION IN ER+/HER2-METASTATIC POSTMENOPAUSAL BREAST CANCER PATIENTS: RESULTS FROM A RETROSPECTIVE MEDICAL RECORD REVIEW IN THE UNITED STATES

被引：0
|
作者：
Zanotti, G. [1 ]
Hunger, M. [2 ]
Perkins, J. J. [1 ]
Horblyuk, R. [1 ]
Martin, M. [3 ]
机构：
[1] Pfizer Inc, New York, NY USA
[2] Mapi Grp, Munich, Germany
[3] Mapi Grp, Uxbridge, Middx, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1646
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN24
引用
收藏
页码：A137 / A138
页数：2
相关论文
共 50 条
  • [31] Treatment patterns and associated outcomes among patients with HER2+metastatic breast cancer in the United States: an observational cohort study
    Lam, Clara
    Varghese, Della
    Collins, Jenna
    Nordstrom, Beth
    Murphy, Brian
    Mehta, Sandhya
    Faherty, Eleanor
    ONCOLOGIST, 2025, 30 (04):
  • [32] Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2-metastatic breast cancer with low sensitivity to endocrine therapy
    Kikawa, Yuichiro
    Hagiwara, Yasuhiro
    Fujisawa, Tomomi
    Araki, Kazuhiro
    Iwamoto, Takayuki
    Sangai, Takafumi
    Shien, Tadahiko
    Takao, Shintaro
    Nishimura, Reiki
    Takahashi, Masato
    Toyama, Tatsuya
    Aihara, Tomohiko
    Mukai, Hirofumi
    Taira, Naruto
    PLOS ONE, 2022, 17 (11):
  • [33] Real-world treatment patterns and outcomes in ER+/PR+/HER2+metastatic breast cancer (MBC) patients: A National Cancer Database analysis.
    Statler, Abby
    Nahleh, Zeina A.
    Hobbs, Brian
    Wei, Wei
    Gupta, Annie
    Blake, Cassann N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] The treatment patterns, efficacy, and safety of nab®-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis
    Caihua Liang
    Ling Li
    Cindy Duval Fraser
    Amy Ko
    Deyanira Corzo
    Cheryl Enger
    Debra Patt
    BMC Cancer, 15
  • [35] The treatment patterns, efficacy, and safety of nab®-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis
    Liang, Caihua
    Li, Ling
    Fraser, Cindy Duval
    Ko, Amy
    Corzo, Deyanira
    Enger, Cheryl
    Patt, Debra
    BMC CANCER, 2015, 15
  • [36] Real-world clinical outcomes in patients (pts) with HR+/HER2-metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US)
    Tolaney, Sara M.
    Punie, Kevin
    Kurian, Allison W.
    Ntalla, Ioanna
    Verret, Wendy
    Sadetsky, Natalia
    Sjekloca, Nikoleta
    Stokes, Michael
    Jhaveri, Komal L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Systematic review and meta-analysis of post-progression outcomes in ER+/HER2-metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials
    Munzone, E.
    Pagan, E.
    Bagnardi, V
    Montagna, E.
    Cancello, G.
    Dellapasqua, S.
    Iorfida, M.
    Mazza, M.
    Colleoni, M.
    ESMO OPEN, 2021, 6 (06)
  • [38] Characteristics, treatment patterns, and survival from three cohorts of advanced or metastatic cancer patients using health care claims data in the United States.
    Beachler, Daniel C.
    Lamy, Francois-Xavier
    Russo, Leo J.
    Lanes, Stephan
    Dinh, Jade
    Taylor, Devon H.
    Yin, Ruihua
    Jamal-Allial, Aziza
    Verpillat, Patrice
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27)
  • [39] Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2-Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice
    Ring, Alistair
    Karuturi, Meghan
    Smyth, Emily Nash
    Lokhandwala, Tasneem
    Sheffield, Kristin M.
    Willey, Joanne
    Lunacsek, Orsolya
    Sapunar, Francisco
    Cui, Zhanglin Lin
    Coutinho, Anna D.
    Rybowski, Sarah
    DRUGS-REAL WORLD OUTCOMES, 2023, 10 (04) : 589 - 603
  • [40] Systematic review and meta-analysis of post-progression outcomes in ER+/HER2-metastatic breast cancer after treatment with endocrine therapy and CDK 4/6 inhibitors within randomized clinical trials.
    Munzone, Elisabetta
    Pagan, Eleonora
    Bagnardi, Vincenzo
    Montagna, Emilia
    Cancello, Giuseppe
    Dellapasqua, Silvia
    Iorfida, Monica
    Mazza, Manuelita
    Colleoni, Marco
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345